



The 25th Congress of the Asian Pacific Society of Respiriology (APSR 2021)
Co-sponsored by Boehringer Ingelheim

Sponsored Symposium 1

Progressive fibrosing interstitial lung diseases(PF-ILD) -Disease concept, Monitoring, Treatment.

When: Saturday 20 November 2021, 18:00-19:30 (JST)

Where: This seminar will be held by Online
The registration for participating APSR 2021, Please check official web site.

Agenda

Chair 1: Prof. Takafumi Suda

Chair 2: Prof. Yoshikazu Inoue

Speaker 1: Prof. Yoshikazu Inoue

Speaker 2: Prof. Masataka Kuwana

Speaker 3: Prof. Vincent Cottin

Time	Chair	Presentation	Speaker
18:00-18:30 JST	Prof. Takafumi Suda	Emerging concept and pathogenesis of PF-ILD	Prof. Yoshikazu Inoue
18:30-19:00 JST		Diagnosis and monitoring of CTD-ILD	Prof. Masataka Kuwana
19:00-19:30 JST	Prof. Yoshikazu Inoue	Impact of treatment of PF-ILD	Prof. Vincent Cottin

Biographies



Prof. Takafumi Suda

Hamamatsu University School of Medicine, Shizuoka, JAPAN

Takafumi Suda is Professor of Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. This facility is one of Japan's leading clinical and research institutes for interstitial lung diseases, and provides advanced treatment and care for many patients with interstitial lung diseases.

Professor Suda is conducting basic and clinical research on idiopathic interstitial pneumonias, interstitial lung diseases associated with collagen vascular diseases, sarcoidosis, hypersensitivity pneumonitis, and other rare interstitial lung diseases. He has published numerous treatises on interstitial lung disease. In particular, he and his group recently developed nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion in Japan. He has been also involved in many clinical trials for idiopathic pulmonary fibrosis as well as other interstitial lung diseases.

Professor Suda serves as a managing director of the Japanese Respiratory Society, and is also an officer of the Japanese Respiratory Society's Academic Committee on Diffuse Lung Disease. He is in charge of the research representative of the research group on diffuse lung disease of the intractable disease practical application project of the Ministry of Health, Labor and Welfare of Japan.



Prof. Yoshikazu Inoue

National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan

Dr. Yoshikazu Inoue is an executive director of clinical research center, National Hospital Organization Kinki-Chuo Chest Medical Center (Osaka, Japan) and an Invited Professor, Infection, Immunology and Oncology Cooperating Course, Graduate School of Medicine, Osaka University. He earned M.D. and Ph.D. from Ehime University School of Medicine (Ehime, Japan), and studied about interstitial lung diseases (ILDs) at University of Colorado, Health Science Center, National Jewish Center for Immunology and Respiratory Medicine, Occupational and Environmental Section, Pulmonary Division as a post graduate fellow (Denver, Colorado, USA). He has spent his professional career focusing on translational and clinical aspects of ILDs, including idiopathic interstitial pneumonias, connective tissue disease-ILDs, occupational and environmental lung diseases, rare intractable lung diseases (pulmonary alveolar proteinosis, lymphangioleiomyomatosis). He has conducted and involved in many international clinical trials and cohort studies including IMPULSIS and INBUILD studies as a global steering committee member. He has served as presidents, delegates, and board members of domestic and international scientific society including ATS, ERS, APSR, Fleischner Society, WASOG, JRS, JSSOG, etc.. Recently, he was a president of the Fleischner Society in 2020, and a president of JSSOG in 2021. He has published more than 400 original articles, review articles, and case reports. He has served as advisors of patient advocacy groups such as LAM Foundation, PAP Foundation, Japanese PAP society, Japanese LAM Patients Society. He was awarded the LAM foundation Scientific Advancement Award in 2015.



Prof. Masataka Kuwana

Department of Allergy and Rheumatology,
Nippon Medical School Graduate School of Medicine, Tokyo, Japan

Dr. Masataka Kuwana is a professor of allergy and rheumatology and a director of scleroderma and myositis at the center of excellence at Nippon Medical School in Tokyo, Japan. He was trained at Keio University and joined the Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, as a postdoctoral fellow. Since completion of the fellowship program, Dr. Kuwana has spent his professional career focusing on basic and clinical aspects of systemic sclerosis, myositis, and a variety of systemic and organ-specific autoimmune diseases. He has published more than 400 peer-reviewed scientific articles and written more than 10 book chapters. He is listed as an editorial board member of 7 peer-reviewed journals, and serves as an Editor-in-Chief of Modern Rheumatology and the Journal of Scleroderma and Related Disorders. Dr. Kuwana is considered an internationally recognized leading expert in systemic sclerosis, myositis, pulmonary hypertension, interstitial lung disease, and autoimmunity.



Prof. Vincent Cottin

Louis Pradel Hospital, Claude Bernard University Lyon 1, Lyon, France

Vincent Cottin is Professor of Respiratory Medicine and Coordinator of the National Reference Centre for Rare Pulmonary Diseases at the Louis Pradel Hospital and the Claude Bernard University Lyon, France. The centre has pioneered the clinical care and research of patients with rare and so-called orphan lung diseases for many years, and has set up the OrphaLung network coordinated by Professor Cottin of 21 expert centres throughout France. The centre has been recognised as the only centre in France to be part of the European Reference Network for interstitial lung disease (ERN-LUNG, ILD).

Professor Cottin's research interests include rare 'orphan' pulmonary diseases including IIPs and especially IPF, as well as connective tissue disease including systemic sclerosis. More specifically, he has contributed to characterising and individualising the syndrome of combined pulmonary fibrosis and emphysema, fostering research by his group and many investigators on this combination. He is an investigator and member of the Steering Committee, or Data Safety Monitoring Board, of many clinical trials on IPF, and is conducting personal research on combined pulmonary fibrosis and emphysema.

Professor Cottin has served as elected Head of the ERS Clinical Assembly from 2009 to 2012. He has been Chief Editor of the European Respiratory Review, and is currently Section Editor of the European Respiratory Journal and Associate Editor of Respiration. He has recently edited a book on orphan lung diseases and is preparing a second edition. He is an appointed Fellow of the European Respiratory Society (FERS) and has been awarded the ERS Gold Medal of IPF.